

1 Device-related complications in the subcutaneous and transvenous ICD: 2 a secondary analysis of the PRAETORIAN trial


3
4 Reinoud E. Knops, MD, PhD¹ *; Shari Peppinkhuizen, MD¹ *; Peter Paul H.M. Delnoy, MD, PhD²; Lucas V.A.
5 Boersma, MD, PhD^{1,3}; Juergen Kuschyk, MD^{4,5}; Mikhael F. El-Chami, MD⁶; Hendrik Bonnemeier, MD, PhD⁷;
6 Elijah R. Behr, MD^{8,9}; Tom F. Brouwer, MD, PhD¹; Stefan Kaab, MD, PhD^{10,11,17}; Suneet Mittal, MD¹²; Anne-
7 Floor B.E. Quast, MD, PhD¹; Willeke van der Stuijt, MD¹; Lonneke Smeding, PhD¹; Jolien A. de Veld, MD¹; Jan
8 G.P. Tijssen, PhD¹; Nick R. Bijsterveld, MD, PhD¹³; Sergio Richter, MD¹⁴; Marc A. Brouwer, MD, PhD¹⁵; Joris R.
9 de Groot, MD, PhD¹; Kirsten M. Kooiman, MPA¹; Pier D. Lambiase, MD, PhD¹⁶; Petr Neuzil, MD, PhD¹⁸; Kevin
10 Vernooij, MD, PhD¹⁹; Marco Alings, MD, PhD^{20,21}; Timothy R. Betts, MD²²; Frank A.L.E. Bracke, MD, PhD²³;
11 Martin C. Burke, DO²⁴; Jonas S.S.G. de Jong, MD, PhD²⁵; David J. Wright, MD²⁶; Ward P.J. Jansen, MD, PhD²⁷;
12 Zachary I. Whinnett, MD, PhD²⁸; Peter Nordbeck, MD²⁹; Michael Knaut, MD³⁰; Berit T. Philbert, MD³¹; Jurren M.
13 van Opstal, MD, PhD³²; Alexandru B. Chicos, MD³³; Cornelis P. Allaart, MD, PhD³⁴; Alida E. Borger van der Burg,
14 MD, PhD³⁵; Jose M. Dizon, MD³⁶; Marc A. Miller, MD³⁷; Dmitry Nemirovsky, MD³⁸; Ralf Surber, MD³⁹; Gaurav A.
15 Upadhyay, MD⁴⁰; Raul Weiss, MD⁴¹; Anouk de Weger, MSc¹; Arthur A.M. Wilde, MD, PhD^{1,17} *; Louise R.A.
16 Olde Nordkamp, MD, PhD¹ * On behalf of the PRAETORIAN Investigators

17 * R.E. Knops and S. Peppinkhuizen contributed equally to this study.

18 † A.A.M. Wilde and L.R.A. Olde Nordkamp contributed equally to this study.

19
20 ¹Amsterdam UMC location University of Amsterdam, Heart Center, Department of Cardiology, Amsterdam, The Netherlands;
21 Amsterdam Cardiovascular Sciences Heart failure & arrhythmias, Amsterdam, the Netherlands; ²Department of Cardiology, Isala
22 Heart Centre, Zwolle, The Netherlands; ³Department of Cardiology, St. Antonius Hospital, Nieuwegein, The Netherlands; ⁴First
23 Department of Medicine, University Medical Center Mannheim, Mannheim, Germany; ⁵German Center for Cardiovascular
24 Research Partner Site Heidelberg, Mannheim, Germany; ⁶Division of Cardiology Section of Electrophysiology,
25 Emory University, Atlanta, GA, United States; ⁷Klinik für Innere Medizin III, Schwerpunkt Kardiologie und Angiologie,
26 Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany; ⁸St George's University of London, London, United
27 Kingdom; ⁹St George's University hospitals NHS Foundation Trust, London, United Kingdom; ¹⁰Department of Medicine I,
28 Ludwig-Maximilians University Hospital, München, Germany; ¹¹German Center for Cardiovascular Research, Munich Heart
29 Alliance, Munich, Germany; ¹²The Valley Health System, Ridgewood, NJ, United States; ¹³Department of Cardiology,
30 Flevoziekenhuis, Almere, the Netherlands; ¹⁴Department of Electrophysiology, Heart Center at University of Leipzig, Leipzig,
31 Germany; ¹⁵Department of Cardiology, Radboud University Medical Center, Nijmegen, the Netherlands; ¹⁶Office of the Director
32 of Clinical Electrophysiology Research and Lead for Inherited Arrhythmia Specialist Services, University College London and
33 Barts Heart Centre, London, United Kingdom; ¹⁷European Reference Network for rare, low prevalence and complex diseases of
34 the heart: ERN GUARD-Heart; <http://guardheart.ern-net.eu>; ¹⁸Department of Cardiology, Homolka Hospital, Prague, Czech
35 Republic; ¹⁹Department of Cardiology, Cardiovascular Research Institute Maastricht, Maastricht University Medical Center,
36 Maastricht, the Netherlands; ²⁰Department of Cardiology, Amphia Hospital, Breda, the Netherlands; ²¹Werkgroep Cardiologische
37 Centra Nederland, Utrecht, the Netherlands; ²²Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust,
38 Oxford, United Kingdom; ²³Department of Electrophysiology, Catharina Hospital Eindhoven, Eindhoven, the Netherlands;
39 ²⁴CorVita Science Foundation, Chicago, IL, United States; ²⁵Department of Cardiology, OLVG, Amsterdam, Netherlands;
40 ²⁶Liverpool Heart and Chest Hospital, Liverpool, United Kingdom; ²⁷Department of Cardiology, Tergooi MC, Blaricum, The
41 Netherlands; ²⁸National Heart and Lung Institute, Imperial College London, London, United Kingdom; ²⁹University and
42 University Hospital Würzburg, Würzburg, Germany; ³⁰Heart Surgery, Heart Center Dresden, Carl Gustav Carus Medical Faculty,
43 Dresden University of Technology, Dresden, Germany; ³¹Department of Cardiology, The Heart Centre, Rigshospitalet, University
44 of Copenhagen, Copenhagen, Denmark; ³²Medical Spectrum Twente, Enschede, the Netherlands; ³³Division of Cardiology,
45 Northwestern Memorial Hospital, Northwestern University, Chicago, IL, United States; ³⁴Department of Cardiology, and
46 Amsterdam Cardiovascular Sciences (ACS), Amsterdam UMC, Location VUMC, Amsterdam, The Netherlands; ³⁵Medisch
47 Centrum Leeuwarden, Leeuwarden, The Netherlands; ³⁶Department of Medicine - Cardiology, Columbia University Irving
48 Medical Center, New York, NY, United States; ³⁷Icahn School of Medicine at Mount Sinai, Mount Sinai Hospital, New York,
49 NY, United States; ³⁸Cardiac Electrophysiology Division, Department of Medicine, Englewood Hospital and Medical Center,
50 Englewood, NJ, United States; ³⁹Department of Internal Medicine I, Jena University Hospital, Jena, Germany; ⁴⁰Center for
51 Arrhythmia Care, Heart and Vascular Institute, University of Chicago Pritzker School of Medicine, Chicago, IL, United States;
52 ⁴¹Division of Cardiovascular Medicine, College of Medicine, The Ohio State University, Columbus, OH, United States

1 Corresponding author and Address:
 2 R.E. Knops, MD, PhD Amsterdam UMC location University of Amsterdam, Heart Center, Department of
 3 Cardiology, Amsterdam, The Netherlands; Amsterdam Cardiovascular Sciences Heart failure & arrhythmias,
 4 Amsterdam, the Netherlands Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands 0031(20)- 566 5424
 5 r.e.knops@amsterdamumc.nl
 6



Structured Graphical Abstract 160x108 mm (.58 x DPI)

7
8
9

1 Introduction

2
3 Implantable cardioverter-defibrillator (ICD) therapy is an effective therapy for the prevention of sudden
4 cardiac death, but comes with the risk of device-related complications (1-4). At 10 years post implant, the
5 risk of lead failure can be as high as 25% in patients with a transvenous ICD (TV-ICD)(5). The
6 subcutaneous ICD (S-ICD) is a completely extravascular ICD and was developed to overcome lead-
7 related complications (6). Currently, the S-ICD is considered a safe and viable alternative for TV-ICD
8 therapy (7-9). Registries have shown that S-ICD therapy is associated with a complication rate of up to
9 15% in 5-year follow-up compared to 14% in the TV-ICD (4, 9-12). However, the morbidity and clinical
10 relevance of complications in S-ICD patients differ compared to complications related to TV-ICD patients
11 (13).

12 The PRAETORIAN trial is the first randomised controlled trial comparing the S-ICD and TV-ICD and
13 demonstrated that the S-ICD is non-inferior to the TV-ICD with regard to the composite endpoint of
14 device-related complications and inappropriate shocks in a general ICD population (14). In this primary
15 analysis, device-related complications alone were shown to be not statistically different between S-ICD
16 and TV-ICD. Since device-related complications after device implantation vary greatly in morbidity and
17 clinical relevance, this prespecified secondary analysis of the PRAETORIAN trial analyses the type,
18 nature and timing of complications and evaluates the clinical consequences in patients implanted with an
19 S-ICD or TV-ICD.

20 Methods

21 22 *Design and population of the PRAETORIAN trial*

23 The PRAETORIAN trial is an international, multicenter, randomised controlled trial in which 849 patients
24 were randomised 1:1 to receive an S-ICD or TV-ICD. Rationale and design of the PRAETORIAN trial
25 were described in length elsewhere (15). In brief, patients with a class I or IIa indication for ICD therapy

1 and without the need for bradycardia pacing or cardiac resynchronisation therapy were included from
2 March 2011 until January 2017 and randomised to S-ICD or TV-ICD therapy. Key exclusion criteria were
3 a known ventricular tachycardia (VT) below 170 bpm or therapy refractory monomorphic VT. A dual
4 chamber device that is specifically deemed necessary for arrhythmia discrimination was allowed per
5 protocol. The primary endpoint was the composite of inappropriate shocks and device-related
6 complications. Patients were followed for a median of 49 months. ICD programming was mandated by
7 protocol in both arms. All complications were collected, monitored and adjudicated by a clinical events
8 committee (CEC). All participating centers were required to have ample experience with implanting both
9 devices. Implant procedure and follow-up were per local routine. The PRAETORIAN study protocol was
10 approved by the institutional medical ethics committees and all patients provided written informed
11 consent.

12 13 *Endpoints and definitions*

14 In this prespecified secondary analysis all complications adjudicated by the CEC as device-related were
15 analysed. Device-related complications included: device-related infections that resulted in a lead or
16 generator extraction; pocket bleedings - also called pocket hematoma - that required drain insertion, blood
17 transfusion or prolonged hospitalisation; device-related thrombotic events; pneumothorax or hemothorax
18 that led to intervention or prolongation of hospitalisation; lead perforation; tamponade; lead repositioning
19 and other complications related to the lead or generator that led to medical or surgical intervention.
20 Generator replacements due to normal battery depletion were not included as device-related
21 complications.

22 Lead-related complications were defined as complications directly caused by insertion or chronic
23 placement of the ICD lead, or leading to extraction, repositioning or replacement of the ICD lead.
24 Systemic infections were defined as infections with positive blood cultures and sepsis was defined as a
25 dysregulated host response to infection causing life-threatening organ dysfunction (16). Acute

1 complications were defined as device-related complications occurring within ≤ 30 days and late
2 complications were defined as complications occurring more than 30 days after device implantation.
3 Procedure-related complications were defined as complications within 30 days including device-related
4 bleeding, thrombotic event, defibrillation test failure, perforation, tamponade, pneumothorax and
5 implantation failure. Lead and/or device repositioning, lead and/or device replacements, device
6 extractions, pocket explorations or drain insertions after initial implantation or implantation attempt were
7 considered invasive interventions.

8 9 *Statistical analysis*

10 All data were analysed using an intention-to-treat analysis. An as-treated analysis was also performed for
11 lead-related complications. Descriptive statistics are reported as mean \pm standard deviation or median with
12 interquartile range (IQR) for continuous variables and numbers and percentages for categorical variables.
13 Baseline variables were compared using the Fisher exact test, χ^2 test, Student *t*-test, or Mann-Whitney U
14 test, as appropriate. For time to event variables, Kaplan-Meier curves displaying the pattern of events were
15 constructed and 48-month Kaplan-Meier estimates of the event rate are reported for both study groups and
16 compared using log-rank tests. Participants without events were censored at their last known event-free
17 time point. Hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated by Cox proportional
18 hazard models. The proportional hazard assumptions were assessed by scaled Schoenfeld residuals and
19 visually comparing the plot of the log of cumulative hazard between treatments. Univariable and
20 multivariable Cox proportional hazard models were performed to find predictors for device-related
21 complications and device-related complications requiring invasive interventions. Two-sided P-values
22 <0.05 were considered statistically significant. P-values were not adjusted for multiplicity. All statistical
23 analyses were performed using R software version 4.0.3 (RStudio PBC).

24

1 Results

2 *Patient characteristics*

3 A total of 849 patients were randomised to an S-ICD (N=426) or TV-ICD (N=423). Details and primary
4 results of the PRAETORIAN trial are published elsewhere (14). Baseline characteristics of the total cohort
5 are indicated in Table S1. In short, median age was 63 years (IQR, 54-69 years) in the S-ICD group and
6 64 years (IQR, 56-70 years) in the TV-ICD group, 20.9% were female in the S-ICD group and 18.4% in
7 the TV-ICD group, 67.8% had an ischemic cardiomyopathy in the S-ICD group and 70.4% in the TV-ICD
8 group. In the S-ICD group 81.2% and in the TV-ICD group 80.1% received the ICD for primary
9 prevention. The median follow-up time was 48.0 months in the S-ICD group and 50.6 months in the TV-
10 ICD group. Implant experience per implanter, median implantation duration, incision technique, use of
11 prophylactic antibiotics, use of general anaesthesia and defibrillation test (DFT) performance are given in
12 Table S2.

13 Thirty-one patients in S-ICD group experienced a total of 36 device-related complications and 44 patients
14 in the TV-ICD group had a total of 49 device-related complications. There was no statistical difference in
15 the total number of patients experiencing a device-related complication in the S-ICD group and TV-ICD
16 group (48-month Kaplan-Meier estimated cumulative incidence, 5.9% and 9.8%, respectively; HR, 0.69
17 [95% CI 0.44-1.09]; $P=0.11$, Figure 1). In the TV-ICD group 3 (6.8%) patients had a dual chamber ICD
18 implanted and 2 (4.5%) patients had a CRT-D implanted. In the S-ICD group one patient had a dual
19 chamber TV-ICD (3.2%) at the time of experiencing a device-related complication. Four patients in the S-
20 ICD group and 5 patients in the TV-ICD group experienced more than one device-related complication
21 during follow up (Table S3). Median time from initial implant to first device-related complication was 11
22 days (IQR 1-1218 days) in the S-ICD group and 41 days (IQR 2-736 days) in the TV-ICD group ($P=0.78$).
23 The median age of patients experiencing a complication in the S-ICD group was 65 years (IQR, 58-69
24 years) and 62 years (IQR, 56-70) in the TV-ICD group. The characteristics of patients with device-related
25 complications were similar in both arms except for the history of atrial fibrillation (AF) which was

1 significantly higher in the S-ICD group (41.9% vs. 6.8%, $P = <0.001$, Table 1). A comparison of the
2 baseline characteristics of patients with and without device-related complications in both groups is shown
3 in Table S4. A history of AF was a positive predictor for device-related complications in the S-ICD group
4 and a negative predictor in the TV-ICD group (Table S5). Body mass index (BMI) in the S-ICD group and
5 a history of AF in the TV-ICD group were independent predictors for device-related complications
6 requiring an invasive intervention (Table S6).

8 *Type of device-related complications*

9 The most common device-related complications in the S-ICD group were pocket bleedings (8/36) whereas
10 lead dysfunctions (9/49) and infections (8/49) were most prominent in the TV-ICD group (Table 2). In the
11 S-ICD group, 3 out of 8 patients with a pocket bleeding had a history of AF. In 5 out of 8 patients (62.5%)
12 in the TV-ICD group the infection was systemic with severe morbidity, with three patients having a
13 sepsis, one critically ill patient with a concomitant pulmonary embolism, and one patient with a multifocal
14 pneumonia with acute respiratory failure and need for mechanical ventilation. One of the patients in the
15 TV-ICD group with a pocket infection without systemic involvement did not receive prophylactic
16 antibiotics. Two patients with a systemic infection in the TV-ICD group died within 12 months after
17 device infection. In the S-ICD group four patients (12.9%) experienced a device-related infection, of
18 whom none had a systemic infection ($P=0.03$, Figure 1 and Table 3), and none died within 12 months after
19 device infection.

20 A total of 2 out of 36 patients in the S-ICD group underwent a pulse generator replacement before
21 experiencing a device-related complication. In one of these patients the device-related complication was
22 related to the replacement procedure. Two patients in the S-ICD group had a crossover to a TV-ICD
23 before the device-related complication occurred, due to a non-systemic infection and a sensing issue,
24 respectively. Both patients experienced a lead-related complication after crossover (Table S4). In the TV-

1 ICD group one patient underwent a pulse generator replacement and had a device-related complication
2 related to this replacement procedure. One patient in the TV-ICD group developed a pacing indication 13
3 months after having a crossover to an S-ICD due to TV-ICD implant failure (Table S4 and Table S7).

4 *Lead-related complications*

5 Significantly less patients experienced lead-related complications in the S-ICD group (48-month Kaplan-
6 Meier estimated cumulative incidence 1.4% and 6.6%, respectively; HR 0.24; 95% CI 0.10-0.54; $P<0.001$,
7 Figure 1 and Table 3). In the TV-ICD group, 29 patients had 32 lead-related complications compared to 7
8 patients with 7 lead-related complications in the S-ICD group. Three patients in the TV-ICD group with
9 multiple leads experienced a total of 4 lead-related complications; 2 lead replacements were due to
10 dysfunction of the right ventricular lead and 1 tamponade and 1 pneumothorax occurred in patients with a
11 CRT-D. Table S8 shows an overview of all lead-related complications. In total 4 drain insertions were
12 performed as an intervention after a lead-related complication of which none were associated with a
13 subsequent infection. Two out of seven patients in the S-ICD group experienced a lead-related
14 complication while having a TV-ICD, one was a sensing issue and one was an atrial lead dislocation after
15 having a dual chamber ICD implanted. The as-treated analysis showed five lead-related complications in
16 five (1.0%) patients with an S-ICD and 34 lead-related complications in 31 (7.0%) patients with a TV-
17 ICD ($P<0.001$).

18

19 *Acute and late device-related complications*

20 Eighteen out of 36 (50.0%) and 21 out of 49 (42.9%) of the device-related complications were acute
21 complications in the S-ICD and TV-ICD group, respectively (Table 4). In the S-ICD group, pocket
22 bleedings (7/18) were the most frequent type of acute complication, while in the TV-ICD group lead
23 repositioning was most frequent (6/21) (Table 4). Of the acute complications 11 (61.1%) in the S-ICD
24 group and 13 (61.9%) in the TV-ICD group were procedure-related and four (22.2%) in the S-ICD group
25 and 16 (76.2%) in the TV-ICD group were lead-related. The most frequent late complication in the S-ICD
26 group was the development of a pacing indication (5/18) and in the TV-ICD group a lead replacement

1 (8/28) followed by a device infection (7/28) (Table 4). All five patients in the S-ICD group developed a
2 pacing indication more than one year after device implantation (Table S9). In 2 of these patients a single-
3 chamber pacemaker was implanted, while in the other 3 patients the S-ICD was exchanged for a TV-ICD
4 or CRT-D (Table S7). Half of the total complications occurred in the first 3 months after implantation in
5 both arms (S-ICD 50.0% and TV-ICD 51.0%, Table S9).

6 *Interventions*

7 Patients in the S-ICD group underwent significantly less often invasive interventions as a result of device-
8 related complications compared to the TV-ICD group (48-month Kaplan-Meier estimated cumulative
9 incidence 4.3% vs. 8.3%, HR 0.59; 95% CI 0.35-0.99 $P=0.047$, Figure 1 and Table 3). An overview of the
10 specific interventions per type of device-related complication is shown in Figure 2. In total 25 out of 36
11 device-related complications in the S-ICD group and 42 out of 49 device-related complications in the TV-
12 ICD group required an invasive intervention (Table 5). The most common invasive intervention in the S-
13 ICD group was a crossover (11/25) and in the TV-ICD group a lead replacement (9/42). The most
14 frequent reason for crossover in the S-ICD group was the development of a pacing indication (5/11)
15 followed by an infection (3/11). In the TV-ICD group the most common reason for crossover was an
16 infection (3/6)(Table S7).

17 In the TV-ICD group, 7 out of 8 patients required intravenous antibiotics due to a device-related infection.
18 In the S-ICD group all patients with an infection were treated with oral antibiotics. In 3 out of 8 patients in
19 the TV-ICD group with an infection, the infection occurred within one year after implantation and a lead
20 explantation was performed. In the remaining five patients a lead extraction was performed with and
21 without the use of powered sheaths. After extraction of the S-ICD following infection, an S-ICD was re-
22 implanted in one patient and in the three other patients a TV-ICD was implanted. After extraction of the
23 TV-ICD following infection, three patients received an S-ICD, three patients underwent a re-implantation
24 of a TV-ICD and in two patients the device was extracted without replacement (Figure 2).

1 *Hospitalisation and healthcare burden*

2 A new hospitalisation was required for 24 out of 36 (66.7%) device-related complications in 23 patients in
3 the S-ICD group and for 34 out of 49 (69.4%) device-related complications in 33 patients in the TV-ICD
4 group (Figure 3). In the TV-ICD group 13 (26.5%) complications resulted in a prolonged hospitalisation
5 compared to 11 (30.6%) in the S-ICD group. The median number of additional hospitalisation days was
6 similar in both the S-ICD and TV-ICD group (S-ICD 2.5 (IQR 1-5); TV-ICD 3.0 (IQR 1-7), $P=0.49$). The
7 total number of additional hospital days due to device-related complications was 151 days in the S-ICD
8 group and 354 days in the TV-ICD group.

9 10 Discussion

11
12 This prespecified secondary analysis of the PRAETORIAN trial demonstrated a difference in nature and
13 severity of device-related complications in the S-ICD and TV-ICD. Lead-related complications and
14 systemic infections are significantly lower in the S-ICD group compared to the TV-ICD group. On the
15 other hand, pocket bleedings are more frequent in patients implanted with an S-ICD. In the TV-ICD
16 group, device-related complications resulted in significantly more invasive interventions (Structured
17 Graphical Abstract).

18 The overall device-related complication rate of 5.9% vs. 9.8%, which was included in the primary
19 endpoint of the trial, did not significantly differ between the S-ICD and TV-ICD. The complication rate in
20 the TV-ICD group is comparable to earlier studies (4, 12) whereas the complication rate in the S-ICD
21 group was lower compared to earlier registries (9-11). This is most likely caused by differences in
22 definition of device-related complications and inclusion of centers with limited S-ICD experience in the
23 registries.

1 The more frequent occurrence of pocket bleedings in the S-ICD group might be related to the larger
2 incision and larger pocket necessary for S-ICD implantation due to the larger generator size. Additionally,
3 the majority of patients with a TV-ICD receive a pressure bandage after implantation, while after S-ICD
4 implantation this is less often applied and can explain the more frequent pocket bleedings. Furthermore,
5 anticoagulation strategies before TV-ICD implantation has been extensively studied, but data regarding
6 anticoagulation strategies before S-ICD implantation is lacking and is up to the preference of the implanter
7 (17). A retrospective study of 200 S-ICD patients showed that pocket bleedings in the S-ICD did not
8 appear in patients with interrupted anticoagulation and suggests that interruption without bridging may
9 reduce pocket bleedings after S-ICD implantation (18). However, data on peri-procedural anticoagulation
10 strategies within this trial were not available.

11 Overall, more implant experience may result in a reduction of device-related complications such as pocket
12 bleedings in S-ICD patients (19).

14 *Device-related infections*

15 Patients with a TV-ICD had significantly more systemic infections requiring device extraction. By its
16 intravascular design, infections of the TV-ICD have a higher chance of developing into a systemic
17 infection. A prospective multicentre observational registry of 1099 ICD patients showed that all infections
18 in the TV-ICD were systemic compared to none in the S-ICD (13). In our study, all systemic infections
19 occurred in patients implanted with a TV-ICD, no systemic infections were seen in S-ICD patients.
20 Systemic infections usually have more serious clinical consequences, which is emphasized by the
21 occurrence of sepsis, pulmonary embolism and respiratory insufficiency in the TV-ICD group. The 1-year
22 mortality of a device infection triples from 7% to 24% if the transvenous lead is involved (1). In this
23 study, two out of five patients with a systemic infection died within 1 year after infection related to their
24 TV-ICD. Additionally, if extraction is required, removal of the S-ICD pulse generator and/or leads is less

1 complex and is associated with fewer complications and a lower mortality risk compared to the TV-ICD
2 (20, 21).

3 *Lead-related complications*

4 As expected by the extravascular design of the S-ICD, this study showed significantly less lead-related
5 complications in patients with an S-ICD. This finding is in line with previous meta-analyses of non-
6 randomised studies and confirmed by the recent ATLAS trial (22-24). It was shown previously that
7 implanting more leads results in a higher risk of lead-related complications (25). In the current study, for 2
8 lead-related complications in the TV-ICD group and 1 lead-related complication in the S-ICD group it
9 could not be excluded that the complication was caused by another than the standard right ventricular ICD
10 lead. Patients with a TV-ICD are especially prone to lead failure after multiple years of ICD therapy
11 because of the mechanical traction due to heart motion and arm movements. A large TV-ICD registry
12 showed a lead failure rate of 25% after 10 years (5). A longer follow-up of patients in this study may
13 therefore result in an even higher rate of lead-related complications in the TV-ICD group.
14 Notwithstanding, the S-ICD received an advisory in December 2020 due to 27 reported cases of lead
15 fractures with a calculated occurrence rate of 0.2% at 41 months (26). No lead fractures in the S-ICD were
16 observed in this study: the extended follow-up of the PRAETORIAN trial will put this advisory on lead-
17 related complications in S-ICD patients in further perspective.

18 *Predictors*

19 AF was a positive predictor for device-related complications in the S-ICD group. Whereas this
20 mechanistically could be explained by a higher risk of pocket bleedings due to anticoagulation therapy,
21 the fact that only 3 out of 8 patients with a bleeding in the S-ICD group had a known history of AF
22 suggests that also other mechanisms may play a role. Similarly, the higher number of patients with a
23 history of AF in the S-ICD group cannot be fully explained by the higher number of pocket bleedings in
24 this group. In the TV-ICD group AF was a negative predictor for device-related complications which is in

1 contrast to findings in other studies and might be caused a play of chance, since there does not seem to be
2 a logical mechanistically explanation (27). The choice for a specific device in patients with AF remains a
3 challenge as a history of AF is a risk factor for inappropriate therapy in patients with a TV-ICD (28).

4 BMI was shown to be a positive independent predictor for device-related complications in the S-ICD
5 group requiring an invasive intervention. The extra-vascular nature of the S-ICD and the position of the
6 lead and generator underneath a layer of fat tissue may hamper the attachment of the lead to the fibrotic
7 tissue in patients with a high BMI and therefore these patients may be more prone to lead dislocation. BMI
8 could be a factor during shared decision making when selecting device type. Specifically as a reduced
9 BMI is associated with an increased risk on device complications in the TV-ICD (29). However, more
10 studies with a larger volume of patients and more recent implantation techniques are necessary to further
11 investigate this and to determine potential BMI thresholds.

12 *Invasive interventions and hospitalization*

13 An invasive intervention was more often needed after device-related complications in TV-ICD patients.
14 This was mainly driven by interventions due to lead dysfunction or device-related infections and
15 concomitantly resulted in more hospital admissions. Interventions after S-ICD implant were less often
16 invasive, mainly driven by the non-invasive interventions after a pocket bleeding. It is unknown to what
17 extent this was caused by physicians being more cautious due to having less experience with the S-ICD,
18 and may not be occurring with current standard of care.

19 Crossovers after implantation occurred more frequently from S-ICD to TV-ICD. Whereas development of
20 a pacing indication was an important reason for crossover to TV-ICD, there may also have been a lower
21 threshold for crossover from S-ICD to TV-ICD due to limited initial experience of the implanters and
22 treating centers. An example is crossover to a TV-ICD after a failed DFT with the S-ICD. Current
23 experience is that suboptimal implantation can result in DFT failure and can be managed with
24 repositioning and often improve DFT outcome (30). It can therefore be speculated that, with the increased

1 knowledge of the S-ICD, newer generation S-ICDs and current treatment of complications, the number of
2 S-ICD complications requiring crossover may be lower if the trial would be repeated. New technology by
3 adding a leadless pacemaker for anti-tachycardia pacing or even bradycardia pacing in the future might
4 further reduce the need for crossover (31).

5 The current guidelines of the European Society of Cardiology recommend S-ICD therapy, in the absence
6 of a pacing indication, as an alternative for TV-ICD therapy (32). In this study it was shown that, even in a
7 setting where the S-ICD had a disadvantage of limited implanter experience and therapy optimization,
8 device-related complications in the S-ICD are less severe as they required less often an invasive
9 intervention. Therefore, the S-ICD could become the preferred choice in patients with an ICD indication
10 without need for pacing.

11 A limitation of this study is the difference in experience of the implanters and treating centers with both
12 systems. Whereas centers were selected who had experience with the S-ICD, this was always less than
13 with the TV-ICD, simply due to the shorter availability of the former in clinical practice. The difference in
14 selection of anesthesia during ICD implantation may also have had an unknown effect on device-related
15 complication, for example on post-operative pain and/or discomfort. P-values were not adjusted for
16 multiple comparisons and this should be taken into account when interpreting the results. Furthermore,
17 data regarding implant techniques, such as the type of venous access, and pocket position, were lacking.

18 Conclusion

19 In the primary endpoint of the PRAETORIAN trial, there was no significant difference in overall device-
20 related complications, however the nature and consequences of device-related complications differ. This
21 secondary analysis showed that lead-related complications and systemic infections were more prevalent in
22 the TV-ICD group compared to the S-ICD group, while pocket bleedings were more frequently observed
23 in patients receiving an S-ICD. Device-related complications in the TV-ICD group were considered more
24 severe as they required significantly more often an invasive intervention. These data further clarify the
25 difference between the S-ICD and TV-ICD and contribute to shared decision making in clinical practice.

1 Acknowledgements

2 The authors thank the the patients who participated in this trial, the members of the Clinical Event
3 Committee, for adjudicating all events the members of the data and safety monitoring board, the
4 physicians and the research coordinators for contributions to the conduct of this trial.

5

6 Funding

7 The PRAETORIAN trial was funded by Boston Scientific, which had no role in the design of the trial,
8 analysis of the data, or the drafting and submission of the manuscript (grant number ISROTH20076).

9

10 Conflict of interest

11 Dr Knops reports consultancy fees and research grants from Abbott, Boston Scientific, Medtronic, and
12 Cairdac and has stock options from AtaCor Medical Inc. Dr Mittal reports consultancy fees from Boston
13 Scientific. Dr Vernooy reports consultancy fees from Medtronic and Abbott. Dr Burke is a consultant and
14 receives honoraria as well as research grants from Boston Scientific and has equity in and is chief medical
15 officer for AtaCor Medical, Inc. Dr Wright has consultancy arrangements with Boston Scientific and
16 Medtronic and a research grant from Boston Scientific. Dr Nordbeck reports modest speaker honoraria
17 from Biotronik, Boston Scientific, and Medtronic. Dr Miller reports consultancy fees from Boston
18 Scientific. Dr Whinnett is an advisor for Boston Scientific and on the advisory board for Medtronic and
19 Abbot and reports speaker fees from Medtronic. The other authors report no conflicts.

20

21 Data availability statement

22 The data underlying this article are available in the article and in its online supplementary material.

1 References:

2

- 3 1. Tarakji KG, Wazni OM, Harb S, Hsu A, Saliba W, Wilkoff BL. Risk factors for 1-year mortality
4 among patients with cardiac implantable electronic device infection undergoing transvenous lead
5 extraction: the impact of the infection type and the presence of vegetation on survival. *Europace*.
6 2014;16(10):1490-5.
- 7 2. Sohail MR, Uslan DZ, Khan AH, Friedman PA, Hayes DL, Wilson WR, et al. Management and
8 outcome of permanent pacemaker and implantable cardioverter-defibrillator infections. *J Am Coll*
9 *Cardiol*. 2007;49(18):1851-9.
- 10 3. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS, et al. Prophylactic implantation of a
11 defibrillator in patients with myocardial infarction and reduced ejection fraction. *N Engl J Med*.
12 2002;346(12):877-83.
- 13 4. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R, et al. Amiodarone or an implantable
14 cardioverter-defibrillator for congestive heart failure. *N Engl J Med*. 2005;352(3):225-37.
- 15 5. Koneru JN, Jones PW, Hammill EF, Wold N, Ellenbogen KA. Risk Factors and Temporal Trends of
16 Complications Associated With Transvenous Implantable Cardiac Defibrillator Leads. *J Am Heart Assoc*.
17 2018;7(10):e007691.
- 18 6. Bardy GH, Smith WM, Hood MA, Crozier IG, Melton IC, Jordaens L, et al. An Entirely
19 Subcutaneous Implantable Cardioverter-Defibrillator. *N Engl J Med*. 2010;363(1):36-44.
- 20 7. Weiss R, Knight BP, Gold MR, Leon AR, Herre JM, Hood M, et al. Safety and efficacy of a totally
21 subcutaneous implantable-cardioverter defibrillator. *Circulation*. 2013;128(9):944-53.
- 22 8. Boersma L, Barr C, Knops R, Theuns D, Eckardt L, Neuzil P, et al. Implant and Midterm Outcomes
23 of the Subcutaneous Implantable Cardioverter-Defibrillator Registry: The EFFORTLESS Study. *J Am Coll*
24 *Cardiol*. 2017;70(7):830-41.
- 25 9. Gold MR, Lambiase PD, El-Chami MF, Knops RE, Aasbo JD, Bongiorni MG, et al. Primary Results
26 From the Understanding Outcomes With the S-ICD in Primary Prevention Patients With Low Ejection
27 Fraction (UNTOUCHED) Trial. *Circulation*. 2021;143(1):7-17.
- 28 10. Burke MC, Aasbo JD, El-Chami MF, Weiss R, Dinerman J, Hanon S, et al. 1-Year Prospective
29 Evaluation of Clinical Outcomes and Shocks: The Subcutaneous ICD Post Approval Study. *JACC Clin*
30 *Electrophysiol*. 2020;6(12):1537-50.
- 31 11. Lambiase PD, Theuns DA, Murgatroyd F, Barr C, Eckardt L, Neuzil P, et al. Subcutaneous
32 implantable cardioverter-defibrillators: long-term results of the EFFORTLESS study. *Eur Heart J*. 2022.
- 33 12. Ranasinghe I, Parzynski CS, Freeman JV, Dreyer RP, Ross JS, Akar JG, et al. Long-Term Risk for
34 Device-Related Complications and Reoperations After Implantable Cardioverter-Defibrillator
35 Implantation: An Observational Cohort Study. *Ann Intern Med*. 2016;165(1):20-9.
- 36 13. Palmisano P, Ziacchi M, Ammendola E, D'Onofrio A, Dell'Era G, Laffi M, et al. Rate and impact on
37 patient outcome and healthcare utilization of complications requiring surgical revision: Subcutaneous
38 versus transvenous implantable defibrillator therapy. *J Cardiovasc Electrophysiol*. 2021;32(6):1712-23.
- 39 14. Knops RE, Nordkamp L, Delnoy P, Boersma LVA, Kuschyk J, El-Chami MF, et al. Subcutaneous or
40 Transvenous Defibrillator Therapy. *N Engl J Med*. 2020;383(6):526-36.
- 41 15. Olde Nordkamp LR, Knops RE, Bardy GH, Blaauw Y, Boersma LV, Bos JS, et al. Rationale and
42 design of the PRAETORIAN trial: a Prospective, RANdomizEd comparison of subcuTaneOus and
43 tRansvenous ImPLAntable cardioverter-defibrillator therapy. *Am Heart J*. 2012;163(5):753-60.e2.
- 44 16. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third
45 International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *JAMA*. 2016;315(8):801-10.
- 46 17. Birnie DH, Healey JS, Wells GA, Verma A, Tang AS, Krahn AD, et al. Pacemaker or defibrillator
47 surgery without interruption of anticoagulation. *N Engl J Med*. 2013;368(22):2084-93.

- 1 18. Sheldon SH, Cunnane R, Lavu M, Parikh V, Atkins D, Reddy YM, et al. Perioperative hematoma
2 with subcutaneous ICD implantation: Impact of anticoagulation and antiplatelet therapies. *Pacing Clin*
3 *Electrophysiol.* 2018;41(7):799-806.
- 4 19. Knops RE, Brouwer TF, Barr CS, Theuns DA, Boersma L, Weiss R, et al. The learning curve
5 associated with the introduction of the subcutaneous implantable defibrillator. *Europace.*
6 2016;18(7):1010-5.
- 7 20. van der Stuijt W, Quast ABE, Baalman SWE, de Wilde KC, Brouwer TF, Wilde AAM, et al.
8 Complications related to elective generator replacement of the subcutaneous implantable defibrillator.
9 *Europace.* 2021;23(3):395-9.
- 10 21. Brouwer TF, Driessen AHG, Olde Nordkamp LRA, Kooiman KM, de Groot JR, Wilde AAM, et al.
11 Surgical Management of Implantation-Related Complications of the Subcutaneous Implantable
12 Cardioverter-Defibrillator. *JACC Clin Electrophysiol.* 2016;2(1):89-96.
- 13 22. Rordorf R, Casula M, Pezza L, Fortuni F, Sanzo A, Savastano S, et al. Subcutaneous versus
14 transvenous implantable defibrillator: An updated meta-analysis. *Heart Rhythm.* 2021;18(3):382-91.
- 15 23. Fong KY, Ng CJR, Wang Y, Yeo C, Tan VH. Subcutaneous Versus Transvenous Implantable
16 Defibrillator Therapy: A Systematic Review and Meta-Analysis of Randomized Trials and Propensity
17 Score-Matched Studies. *J Am Heart Assoc.* 2022;11(11):e024756.
- 18 24. Healey J. The ATLAS trial: avoid transvenous leads in appropriate subjects. *HRS 2022; April 30,*
19 *2022; San Francisco, CA2022.*
- 20 25. Kirkfeldt RE, Johansen JB, Nohr EA, Moller M, Arnsbo P, Nielsen JC. Risk factors for lead
21 complications in cardiac pacing: a population-based cohort study of 28,860 Danish patients. *Heart*
22 *Rhythm.* 2011;8(10):1622-8.
- 23 26. Boston Scientific. Important medical device advisory: Boston Scientific; Decemebr 2020
24 [Available from: [https://www.bostonscientific.com/content/dam/bostonscientific/quality/dlt/reg-code-](https://www.bostonscientific.com/content/dam/bostonscientific/quality/dlt/reg-code-228/2020Dec_BSC_EmblemElectrode3501_PhysLtr_Final.pdf)
25 [228/2020Dec_BSC_EmblemElectrode3501_PhysLtr_Final.pdf](https://www.bostonscientific.com/content/dam/bostonscientific/quality/dlt/reg-code-228/2020Dec_BSC_EmblemElectrode3501_PhysLtr_Final.pdf).
- 26 27. Köbe J, Wasmer K, Andresen D, Kleemann T, Spitzer SG, Jehle J, et al. Impact of atrial fibrillation
27 on early complications and one year-survival after cardioverter defibrillator implantation: results from
28 the German DEVICE registry. *Int J Cardiol.* 2013;168(4):4184-90.
- 29 28. Brouwer TF, Knops RE, Kutya V, Barr C, Mondesert B, Boersma LVA, et al. Propensity score
30 matched comparison of subcutaneous and transvenous implantable cardioverter-defibrillator therapy in
31 the SIMPLE and EFFORTLESS studies. *Europace.* 2018;20:F240-F8.
- 32 29. Kirkfeldt RE, Johansen JB, Nohr EA, Jørgensen OD, Nielsen JC. Complications after cardiac
33 implantable electronic device implantations: an analysis of a complete, nationwide cohort in Denmark.
34 *Eur Heart J.* 2014;35(18):1186-94.
- 35 30. Quast A, Baalman SWE, Brouwer TF, Smeding L, Wilde AAM, Burke MC, et al. A novel tool to
36 evaluate the implant position and predict defibrillation success of the subcutaneous implantable
37 cardioverter-defibrillator: The PRAETORIAN score. *Heart Rhythm.* 2019;16(3):403-10.
- 38 31. Tjong FVY, Koop BE. The modular cardiac rhythm management system: the EMPOWER leadless
39 pacemaker and the EMBLEM subcutaneous ICD. *Herzschrittmacherther Elektrophysiol.* 2018;29(4):355-
40 61.
- 41 32. Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J, et al. 2015 ESC
42 Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden
43 cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the
44 Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by:
45 Association for European Paediatric and Congenital Cardiology (AEPC). *Eur Heart J.* 2015;36(41):2793-
46 867.

47

1 Figure legends

2
3 **Figure 1. Time-to-First-Event Curves for total device-related complications, device-related complications**
4 **requiring invasive intervention and lead-related complications**

5 Shown are the cumulative event rates of the first occurrence of device-related complications (A), device-related
6 complication requiring invasive intervention (B), and lead-related complications (C). Hazard ratios are derived from
7 Cox regressions and indicate the relative risk (subcutaneous ICD vs. transvenous ICD) of the endpoint. P-values
8 were not adjusted for multiple comparisons.

9 ICD implantable cardioverter-defibrillator, S-ICD subcutaneous ICD, TV-ICD transvenous ICD.

10
11 **Figure 2. Type of intervention after device-related complications**

12 Shown are the different interventions after a specific device-related complication in the S-ICD group (A) and the
13 different interventions after a specific device-related complication in the TV-ICD group (B). Details on type of non-
14 invasive interventions are presented in Table 5.

15 DFT defibrillator threshold testing, ICD implantable cardioverter-defibrillator, S-ICD subcutaneous ICD, TV-ICD
16 transvenous ICD.

17
18 **Figure 3. Burden of device-related complications on the healthcare system**

19 Shown is the burden of device-related complications on new hospitalizations, prolonged hospitalizations and visits to
20 the outpatient clinic.

21 ICD implantable cardioverter-defibrillator, S-ICD subcutaneous ICD, TV-ICD transvenous ICD.

22
23 **Graphical Abstract**

24 Shown is the summary of the main endpoints of the manuscript: Device-related complications in the subcutaneous
25 and transvenous ICD: a secondary analysis of the PRAETORIAN trial .

26 ICD implantable cardioverter-defibrillator.

27
28

1 Table 1. Baseline characteristics of patients with device-related complications

	Patients with a device-related complication (N=75)		
	Subcutaneous ICD (N=31)	Transvenous ICD (N=44)	P-value
Age, years, median (IQR)	65 (58-69)	62 (56-70)	0.47
Female sex, n (%)	6 (19.4)	11 (25.0)	0.78
Diagnosis, n (%)			0.64
Ischemic cardiomyopathy	22 (71)	35 (79.5)	
Non-ischemic cardiomyopathy	7 (22.6)	7 (15.9)	
Inherited cardiac disease	2 (6.5)	1 (2.3)	
Hypertrophic cardiomyopathy	1 (3.2)	1 (2.3)	
Hypertrophic cardiomyopathy and Brugada	1 (3.2)	0	
Idiopathic ventricular fibrillation	0	1 (2.3)	
Secondary prevention, n (%)	3 (9.7)	4 (9.1)	1.0
Ejection fraction, %, median (IQR)	28 (23-32)*	29 (20-30)†	0.99
NYHA class, n (%)			0.15
I	14 (45.2)	12 (27.3)	
II	12 (38.7)	27 (61.4)	
III/IV	5 (16.1)	5 (11.4)	
Body mass index, kg/m ² , median (IQR)	27.4 (25.0-31.0)	27.1 (23.9-30.8)	0.46
History of atrial fibrillation, n (%)	13 (41.9)	3 (6.8)	<0.001
History of diabetes, n (%)	11 (35.5)	15 (34.1)	1.0

2 ICD implantable cardioverter-defibrillator, IQR interquartile range, NYHA New York Heart Association.

3 * missing in 1 patient.

4 † missing in 4 patients.

5

6

1 Table 2. Type of device-related complications in the S-ICD and TV-ICD

	S-ICD (N=36)	TV-ICD (N=49)
Infection, n (%)	4 (11.1)	8 (16.3)
Pocket/Pulse generator	3	3
Lead	1*	5*
Bleeding, n (%)	8 (22.2)	2 (4.1)
Thrombotic event, n (%)	1 (2.8)	2 (4.1)*
Pneumothorax, n (%)	0	4 (8.2)*
Lead perforation, n (%)	0	2 (4.1)*
Tamponade, n (%)	0	2 (4.1)*
Lead repositioning, n (%)	2 (5.6)	7 (14.3)*
DFT failure	1	0
Lead dislocation	1*	5
Lead dysfunction	0	2†
Other lead or device complications, n (%)	21 (58.3)	22 (44.9)
Lead replacement, n (%)	3 (8.3)*	9 (18.4)*
Lead dysfunction	0	7‡
Lead dislocation	2†	1
Lead perforation	0	1
Inappropriate therapy	1	0
Device malfunction, n (%)	4 (11.1)	6 (8.2)
Early battery depletion	3	2
Interrogation problem	1	0
Long charging time	0	1
Automatic ICD reset	0	1
Other device malfunction	0	2‡
Sensing issues, n (%)	4 (11.1)*†	0
Pacing indication, n (%)	5 (13.9)	1 (2.0)†
Implantation failure, n (%)	0	3 (6.1)*§
DFT failure with subsequent action, n (%)	3 (8.3)*	0
Pain or discomfort, n (%)	2 (5.6)†	3 (6.1)

2 DFT defibrillator threshold testing, ICD implantable cardioverter-defibrillator, S-ICD subcutaneous ICD, TV-ICD transvenous
3 ICD

4 * Device-related complication that are combined in the endpoint lead-related complications: 1/4 sensing issues in the S-ICD group
5 was a reduced RV sensing of the RV-lead (crossover in S-ICD group); 1/3 DFT failure with subsequent action was included as
6 this one was amongst others related to incorrect lead position; One lead repositioning after DFT failure was not included in this
7 combined endpoint as DFT continued to fail after lead repositioning and was therefore not seen as related to the lead; 1/3 implant
8 failures in the TV-ICD group was included in the lead-related endpoint as in this patient RV-lead positioning was impossible
9 despite multiple attempts.

10 † Crossover prior to complication. Only 1/2 patients with a lead dislocation, 1/4 patient with sensing issues and 1/2 patients with
11 pain or discomfort in the S-ICD group had a crossover to TV-ICD before this complication.

12 ‡ One battery/voltage error, one capacitor charging error.

13 § in 2/3 patient there was no venous access during implantation, in 1/3 patients RV-lead positioning was impossible despite
14 multiple attempts.

15 † 4 patients with a lead dysfunction had an increased threshold of which 2 had also an increased impedance, 2 patients had an
16 undersensing of the RV lead and 3 patients had a lead fracture.

18

1 Table 3. 48-month Kaplan-Meier estimated cumulative incidence of main endpoints

	S-ICD	TV-ICD	P-value*	HR (CI)
Device-related complications	5.9%	9.8%	0.11	0.69 (0.44-1.09)
Invasive interventions	4.3%	8.3%	0.047	0.59 (0.35-0.99)
Lead-related complications	1.4%	6.6%	< 0.001	0.24 (0.10-0.54)
Systemic infections	0	1.2%	0.03	-
Acute complications	3.8%	4.7%	0.49	0.79 (0.41-1.53)

2

3 *P-values were not adjusted for multiple comparisons.

4

5 Table 4. Timing of device-related complications after last implanted device

	30 days	> 30 days	
S-ICD, n (%)	18 (50.0)	18 (50.0)	
Infection	1	3	
Pocket bleeding	7	1*	
Thrombotic event	1	0	
Lead repositioning	2	0	
Other lead or device complication	7	14	
Lead replacement		2	1
Device malfunction		1	3
Sensing issues		1	3
Defibrillation test failure		3	0
Pain or discomfort		0	2
Pacing indication		0	5
TV-ICD, n (%)	21 (42.9)	28 (57.1)	
Infection	1	7	
Bleeding	2	0	
Thrombotic event	0	2	
Perforation	2	0	
Lead repositioning	6	1	
Pneumothorax	4	0	
Tamponade	2	0	
Other lead or device complication	4	18	
Lead replacement		1	8
Device malfunction		0	6
Implantation failure		3	0
Pain or discomfort		0	3
Pacing indication		0	1

6

7 ICD implantable cardioverter-defibrillator, S-ICD subcutaneous ICD, TV-ICD transvenous ICD

8 * Patient underwent an extraction of the S-ICD due to expired ICD indication after which a pocket bleeding occurred.

1 Table 5. Interventions after device-related complications

	S-ICD (N=36)	TV-ICD (N=49)
Invasive interventions, n (%)	25 (69.4)	42 (85.7)
Replacement pulse generator, n (%)	4 (11.1)	4 (8.2)
Replacement lead, n (%)	3 (8.3)	9 (18.4)
Extraction with replacement pulse generator + lead, n (%)	2 (5.6)	4 (8.2)
Extraction without replacement, n (%)	0	2 (4.1)
Crossover, n (%)	11 (30.6)	6 (12.2)*
Repositioning lead, n (%)	2 (5.6)	8 (16.3)
Repositioning pulse generator, n (%)	1 (2.8)	3 (6.1)
Reposition pulse generator + lead, n (%)	1 (2.8)	1 (2.0)†
Pocket exploration, n (%)	1 (2.8)	1 (2.0)
Drain insertion, n (%)	0	4 (8.2)
Non-invasive interventions, n (%)	11 (30.6)	7 (14.3)
Additional DFT, n (%)	2 (5.6)	0
Reprogramming, n (%)	0	1 (2.0)
Blood transfusion, n (%)	3 (8.3)	0
Thrombolysis, n (%)	1 (2.8)	0
Change in medication, n (%)	1 (2.8)	2 (4.1)
Conservative, n (%)	4 (11.1)	4 (8.2)

2
3 DFT defibrillator threshold testing, ICD implantable cardioverter-defibrillator, S-ICD subcutaneous ICD, TV-ICD transvenous
4 ICD

5 * One patient in the TV-ICD group received an S-ICD due to TV-ICD implantation failure and later developed a pacing
6 indication for which a TV-ICD was implanted and received a total of 2 crossovers.

7 † One patient underwent a right sided TV-ICD implantation.
8
9




Figure 1
106x247 mm (.58 x DPI)

1
2
3

1




Figure 2
160x59 mm (.58 x DPI)

2

3

4

5




Figure 3
160x57 mm (.58 x DPI)

6

7

8